J P M O R G A N North America Equity Research 22 June 2026 AbbVie Quick Thoughts on Acquisition of Apogee Therapeutics – Strong Strategic Fit, Builds Out Immunology Pipeline This morning, ABBV announced the acquisition of Apogee Therapeutics for ~ $11bn, and we see the deal as a solid fit for AbbVie as it further builds out the company's pipeline in immunology / atopic dermatitis with the lead asset zumilokibart (long acting IL-13). Thus far, zumilokibart Ph2 data in atopic dermatitis offers efficacy that i ...